What Happened

ByteDance has closed a $290 million funding round for Anew Labs, its newly spun-off AI drug discovery unit, at a $1.5 billion valuation, Reuters reported on September 16, 2026, citing two sources familiar with the matter.

ByteDance will retain a 56% stake in the business post-round. The round was led by HSG (formerly Sequoia China), IDG Capital, and Hillhouse Investment, with 5Y Capital serving as co-lead. Additional participants include Gaorong Ventures, Primavera Venture Partners, Boyu Capital, the state-backed Shanghai Future Industries Fund, and SBP Group as a strategic investor.

Approximately 50 core staff are transferring to the new entity, along with its algorithms, technology platform, and pipeline assets. Volcano Engine — ByteDance's cloud division — will continue providing computing power. The unit is led by Liu Kai, who spent seven years in venture capital at IDG Capital and Fire Stone Investment before joining ByteDance in 2021. Notably, his former firm, IDG Capital, is now one of the lead investors.

Anew Labs has operations in Shanghai, Singapore, and San Jose, California, and listed 36 core team members on its website as of May 2026. The company has developed structure-prediction and protein-design models (Protenix and PXDesign) and has four drug candidates, none yet approved. In April 2026, biology lead Chris Li presented an AI-designed IL-17 inhibitor — one of those four candidates — at the American Association of Immunologists meeting in Boston.

The spin-off was first flagged days earlier by Intelligent Emergence, a 36Kr publication, which described the move as ByteDance's first step toward commercializing its AI-for-science efforts.

Why It Matters

This is one of the largest single rounds for an AI drug discovery platform, and it comes from an unusual parent: a consumer-tech company best known for TikTok and short-form video, not life sciences. The deal signals that AI-for-science has matured enough within big-tech R&D to warrant independent governance, dedicated capital, and external investor scrutiny.

The spin-off structure is the key innovation here. ByteDance retains majority control (56%) and continues supplying compute via Volcano Engine, but brings in external capital and presumably independent board oversight. This is a middle path between full divestiture and keeping the unit buried inside a consumer-tech org — and it could become a template for other tech giants sitting on AI-for-science assets that don't fit their core business logic.

For the broader market, the $1.5B valuation sets a benchmark: pre-clinical AI drug platforms with computational models and early-stage candidates can command unicorn valuations, at least in the current Chinese VC environment. The presence of state-backed capital (Shanghai Future Industries Fund) underscores that Beijing continues to view AI-driven biology as a strategic sector worth subsidizing.

Context worth noting: ByteDance recently secured a $29.6 billion loan — Asia's second-largest this year — partly earmarked for AI infrastructure. The Anew Labs spin-off suggests ByteDance is simultaneously consolidating core AI infrastructure spend while carving out non-core AI-for-science bets into independently capitalized entities.

Who Is Affected

AI drug discovery startups — especially those raising in Asia — now have a concrete valuation comp and syndicate structure to reference. A $1.5B post-money for a pre-clinical platform with four candidates and no approvals is aggressive but not unprecedented in the current cycle.

Large tech companies with AI-for-science initiatives — Google (AlphaFold/Isomorphic Labs), Meta (ESMFold), and others — should watch whether the spin-off-plus-majority-retention model gains traction as a governance template.

Cloud infrastructure providers — Volcano Engine's continued role as Anew Labs' compute backbone means the spin-off doesn't sever the infrastructure dependency. For cloud vendors, this is a reminder that AI-for-science workloads are sticky and long-term.

Strategic Implications

For AI startup founders

If you're building in AI-for-science, the spin-off model — retaining parent-company compute and majority ownership while bringing in external capital — is now a validated path. Consider whether your cap table and governance structure would support a similar carve-out if you're operating inside a larger platform. The Anew Labs deal also shows that having a VC-turned-operator as founder (Liu Kai's IDG background) can help bridge the funding gap, since his former firm ended up leading the round.

For developers/operators building with AI APIs

Anew Labs' models — Protenix for structure prediction and PXDesign for protein design — could eventually become commercially available APIs or open-source releases. Monitor whether ByteDance or Anew Labs open-sources these tools, as that would expand the available toolkit for protein engineering workflows beyond DeepMind's AlphaFold and Meta's ESMFold. For now, these models appear to be internal assets tied to Anew Labs' drug pipeline.

For non-technical business owners evaluating AI tools

AI drug discovery remains pre-revenue for most players. Anew Labs has four candidates and zero approvals — this round is a venture bet on computational platform potential, not a validation of clinical efficacy. If you're evaluating AI-driven drug discovery partnerships, treat commercial claims with skepticism until Phase 2 human data exists. The $1.5B valuation reflects investor appetite for AI platform plays, not proven therapeutic outcomes.

What to Watch Next

Monitor whether Anew Labs open-sources any of its models (Protenix, PXDesign) in the coming months — that would signal a platform strategy beyond internal drug development. Also watch for whether other Chinese tech giants (Alibaba, Tencent, Baidu) follow ByteDance's spin-off template for their own AI-for-science units. Finally, track Anew Labs' clinical pipeline progression: the IL-17 inhibitor presented in April is the most advanced candidate publicly disclosed, and its move toward IND filing would be the first real test of whether the computational platform can produce viable drug candidates.

Frequently Asked Questions

Q: What is Anew Labs and what does it do?

A: Anew Labs is ByteDance's spun-off AI drug discovery unit, valued at $1.5B after a $290M funding round. It develops AI models for protein structure prediction (Protenix) and protein design (PXDesign), and has four pre-clinical drug candidates, including an AI-designed IL-17 inhibitor. ByteDance retains a 56% stake.

Q: Why did ByteDance spin off its AI drug discovery unit?

A: According to Reuters' sources, the split was intended to promote the unit's long-term development, since AI-driven drug discovery follows a different industry logic and management approach from ByteDance's core consumer-tech businesses. The spin-off allows Anew Labs to raise external capital and operate with governance suited to biotech, while ByteDance retains majority ownership and continues supplying compute via Volcano Engine.

Q: Who invested in Anew Labs' $290M round?

A: The round was led by HSG (formerly Sequoia China), IDG Capital, and Hillhouse Investment, with 5Y Capital as co-lead. Other participants include Gaorong Ventures, Primavera Venture Partners, Boyu Capital, the state-backed Shanghai Future Industries Fund, and SBP Group as a strategic investor.